Arginine Composition for PolyQ Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for polyglutamine (PolyQ) diseases, such as inherited spinocerebellar ataxias, dentatorubral palliodoluysian atrophy, and spinal bulbar muscular atrophy, are ineffective and lack safe, effective therapeutic agents that can cross the blood-brain barrier.
Innovation Solution
Development of a pharmaceutical composition containing arginine, which inhibits PolyQ aggregate formation and neurodegeneration by targeting misfolding and aggregation of denatured proteins, demonstrated to be safe and effective in both in vitro and animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for PolyQ diseases, then current therapeutic approaches are applied, but they are ineffective and lack safe, effective therapeutic agents that can cross the blood-brain barrier
Solution Approach 1:
The patent changes the chemical parameter by using arginine (a naturally occurring amino acid) instead of conventional synthetic drugs. Arginine's unique properties including its ability to cross the blood-brain barrier and its chemical chaperone function resolve the contradiction by providing both safety and effectiveness where conventional treatments failed
Solution Approach 2:
The patent employs arginine, a naturally occurring amino acid that is safe for human administration, replacing complex synthetic pharmaceuticals. This approach uses a simple, biocompatible substance that the body can naturally process, achieving therapeutic effect without the harmful side effects of conventional drugs
2Reliability
If arginine is administered to suppress PolyQ aggregate formation, then neurodegeneration is inhibited and blood-brain barrier permeability is achieved, but the safety and effectiveness must be confirmed in clinical settings
Solution Approach 1:
The patent performs preliminary validation by demonstrating arginine's safety and efficacy in preclinical models (in vitro studies and animal models) before human clinical trials. This preliminary action establishes a foundation of safety and effectiveness, reducing the risk and complexity of subsequent clinical validation
Solution Approach 2:
The patent leverages arginine's natural properties as a chemical chaperone that the body already recognizes and processes. Since arginine is a naturally occurring amino acid, the body's own metabolic systems can handle it safely, reducing the need for complex safety monitoring and validation compared to synthetic pharmaceuticals
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Arginine effectively suppresses PolyQ aggregate formation and neurodegeneration, showing high blood-brain barrier permeability and safety, thereby providing a promising therapeutic option for PolyQ diseases.
Implementation Method 1
Chemical chaperones stabilize proteins in their natural conformation and exert anti-aggregating properties by affecting the rate or fidelity of the protein folding reaction
Implementation Method 2
arginine is known to cross the blood brain barrier (BBB)
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides a pharmaceutical composition effective for treatment of the PolyQ diseases, which can be safely administered to humans. The present invention provides a pharmaceutical composition comprising: one selected from the group consisting of arginine, a physiologically acceptable salt thereof, and a solvate thereof, as an active ingredient, in which the pharmaceutical composition is used in treatment or prevention of the PolyQ diseases, and the the PolyQ disease is one selected from the group consisting of Huntington disease, inherited spinocerebellar ataxias, dentatorubral palliodoluysian atrophy, and spinal bulbar muscular atrophy.